New shot shows promise for severe eczema sufferers
NCT ID NCT05549947
First seen Apr 29, 2026 · Last updated May 19, 2026 · Updated 3 times
Summary
This study tested an experimental injection called SHR-1819 in 158 adults with moderate to severe atopic dermatitis (eczema). The goal was to see if it safely reduces skin redness, itching, and rash. Participants received either the drug or a placebo, and doctors measured improvement using standard eczema scores at 16 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE ATOPIC DERMATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Huashan Sub-Hospital of Fudan University
Shanghai, Shanghai Municipality, 200040, China
Conditions
Explore the condition pages connected to this study.